Not FDA-approved
Brain & sleep
PT-141
Evidence
Limited human data
Class
Melanocortin receptor agonist
KEY TAKEAWAY
PT-141 is the research name for bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain. The approved version is sold as Vyleesi. Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. Products sold as PT-141 outside that approved drug are not FDA-approved.
Written by the Veylo editorial team · Updated
November 2026
What it is
Melanocortin receptor agonist
Main uses
Low sexual desire in premenopausal women (as approved bremelanotide)
Key fact
Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. Products sold as PT-141 outside that approved drug are not FDA-approved.
Route
Subcutaneous injection before sexual activity (approved product)
Evidence strength
Limited human data
PT-141 is the research name for bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain. The approved version is sold as Vyleesi.
It acts on melanocortin receptors in the central nervous system that are involved in sexual desire, rather than on blood flow.
Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. Products sold as PT-141 outside that approved drug are not FDA-approved.
Low sexual desire in premenopausal women (as approved bremelanotide).
Nausea, flushing and headache are common, and blood pressure can rise temporarily. Repeated use can darken the skin.
PT-141: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.